Angiogenesis, the formation of new capillaries and blood vessels, is a process involved in tumor growth. And VEGF is a primary mediator of angiogenesi

[ginfreely]

Vascular endothelial growth factor (VEGF) is a primary mediator of angiogenesis

 

[ginfreely]

 

[ginfreely]

Vascular endothelial growth factor (VEGF) is a primary mediator of angiogenesis

VEGF and VEGF receptor-2–mediated signaling and angiogenesis may play a key role in the pathogenesis of gastric cancer and lung cancer.10–12

 

[ginfreely]

Go to:

The Vascular Endothelial Growth Factor Pathway​

Angiogenesis, the formation of new capillaries and blood vessels, is a process involved in tumor growth.9Vascular endothelial growth factor (VEGF) is a primary mediator of angiogenesis in normal physiology and in certain diseases.9 VEGF and VEGF receptor-2–mediated signaling and angiogenesis may play a key role in the pathogenesis of gastric cancer and lung cancer.10–12 The blockade of VEGF receptor-2 signaling inhibits angiogenesis (ie, blood supply) to tumors.12 A number of small molecule inhibitors and antibody-based agents that target the VEGF pathway have been studied across various cancer types.9 In clinical studies, targeting the VEGF receptor-2 pathway has shown promise as a second-line treatment for patients with gastric or lung cancer.10–12
Go to:

Ramucirumab Receives Several FDA Approvals in 2014​

A New Option for Advanced Stomach Cancer​

On April 21, 2014, ramucirumab (Cyramza; Eli Lilly), a human VEGF receptor-2 antagonist, was approved by the US Food and Drug Administration (FDA) as a single agent for the treatment of patients with advanced stomach cancer or GEJ adenocarcinoma that has progressed with or after fluoropyrimidine- or platinum-containing chemotherapy.13 Ramucirumab is a recombinant human immunoglobulin G1 monoclonal antibody, also referred to as an angiogenesis inhibitor (ie, blocking the blood supply to tumors).13